CD70-targeted immunoPET Imaging of Malignant Cancers

Summary

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Conditions

• Renal Cancer
• Renal Clear Cell Carcinoma
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nasopharyngeal Carcinoma

Interventions

DRUG

[18F]F-RESCA-RCCB6

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.

DRUG

[18F]F-RESCA-R8B4

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.

DRUG

[68Ga]Ga-NOTA-R8B4

Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.

DRUG

[18F]F-RESCA-RD06

Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]F-RESCA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RD06 injection.

DRUG

[68Ga]Ga-NOTA-RD06

Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RD06 injection.

Sponsors & Collaborators

• RenJi Hospital

  lead OTHER

Principal Investigators

• Jianjun Liu, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

• Weijun Wei, Ph.D. & M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-12-23

Primary Completion

2026-12-23

Completion

2026-12-23

Countries

• China

Study Locations